Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Rheumatol Int ; 43(8): 1531-1539, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37173547

RESUMEN

Perception of the disease and its management impacts patients with Psoriatic arthritis (PsA) to a great degree. Studies examining patients' viewpoints and perception of their disease and its management are scarce. This multicentric cross-sectional survey was undertaken to understand the perspectives of patients with PsA. A survey questionnaire with items on demographics, awareness about their disease, treatment, physical therapy, quality of life and satisfaction with the care received was designed. After internal and external validation, a pilot survey was conducted, and the questionnaire was finalized. The final survey (with translations in local languages) was carried out at 17 centres across India. There were 262 respondents (56% males) with mean age of 45.14 ± 12.89 years. In 40%, the time lag between onset of symptoms and medical assessment for it was more than a year. In most of the patients, the diagnosis of PsA was made by a rheumatologist. Over 83% of patients were consulting their rheumatologist periodically as advised and fully compliant with the treatment. Lack of time and cost of therapy were the most common reasons for non-adherence to therapy. Eighty-eight patients (34%) were not fully satisfied with their current treatment. Over two-third of patients had never seen a physiotherapist due to barriers including a lack of time, pain, and fatigue. The daily activities and employment status were affected in nearly 50% of patients with PsA. The current survey has identified a gap in patients' awareness levels and helps healthcare providers in understanding the varied perceptions of patients with PsA. Addressing these issues in a systematic manner would potentially improve the treatment approaches, outcomes, and patient satisfaction levels.


Asunto(s)
Artritis Psoriásica , Psoriasis , Masculino , Humanos , Adulto , Persona de Mediana Edad , Femenino , Artritis Psoriásica/diagnóstico , Psoriasis/diagnóstico , Estudios Transversales , Calidad de Vida , Satisfacción del Paciente , Satisfacción Personal
2.
Arthritis Rheumatol ; 73(2): 276-285, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32892503

RESUMEN

OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India. METHODS: A retrospective analysis of pediatric and adult patients with DADA2 diagnosed at various rheumatology centers across India was conducted. Clinical characteristics, diagnostic findings, and treatment responses were analyzed in all subjects. RESULTS: In total, 33 cases of DADA2 were confirmed in this cohort between April 2017 and March 2020. Unlike previous studies, nearly one-half of the confirmed cases presented during adulthood. All symptomatic patients exhibited features of vasculitis, whereas constitutional symptoms and anemia were more common in pediatric patients. Cutaneous and neurologic involvement were common, and 18 subjects had experienced at least one stroke. In addition, the clinical spectrum of DADA2 was expanded by recognition of novel features in these patients, including pancreatic infarction, focal myocarditis, and diffuse alveolar hemorrhage. Treatment with tumor necrosis factor inhibitors (TNFi) was initiated in 25 patients. All of the identified disease manifestations showed marked improvement after initiation of TNFi, and disease remission was achieved in 19 patients. Two cases were complicated by tuberculosis infection, and 2 deaths were reported. CONCLUSION: This report presents the first case series of patients with DADA2 from India, diagnosed by adult and pediatric care providers. The findings raise awareness of this syndrome, particularly with regard to its presentation in adults.


Asunto(s)
Agammaglobulinemia/fisiopatología , Enfermedades Gastrointestinales/fisiopatología , Enfermedades Hematológicas/fisiopatología , Enfermedades Renales/fisiopatología , Enfermedades del Sistema Nervioso/fisiopatología , Inmunodeficiencia Combinada Grave/fisiopatología , Adenosina Desaminasa/genética , Adenosina Desaminasa/metabolismo , Adolescente , Adulto , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/tratamiento farmacológico , Agammaglobulinemia/genética , Edad de Inicio , Anemia/fisiopatología , Niño , Preescolar , Diagnóstico Tardío , Femenino , Glucocorticoides/uso terapéutico , Hemorragia/fisiopatología , Humanos , India , Lactante , Infarto/fisiopatología , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Leucopenia/fisiopatología , Enfermedades Pulmonares/fisiopatología , Masculino , Miocarditis/fisiopatología , Enfermedades Pancreáticas/fisiopatología , Estudios Retrospectivos , Inmunodeficiencia Combinada Grave/diagnóstico , Inmunodeficiencia Combinada Grave/tratamiento farmacológico , Inmunodeficiencia Combinada Grave/genética , Accidente Cerebrovascular/fisiopatología , Resultado del Tratamiento , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Vasculitis/fisiopatología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...